Study to Assess the Efficacy and Safety of a PARP Inhibitor for the Treatment of BRCA-positive Advanced Breast Cancer

• Status: Active, not recruiting
• Trial end date: 2021-12-31
• Target enrollment: 0
• Participant gender: Female

Summary

The purpose of the study is to see if the drug KU 0059436 (olaparib) is effective and well tolerated in treating patients with measurable BRCA1- or BRCA2-positive advanced breast cancer and for whom no curative therapeutic option exists

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: AstraZeneca
• Collaborator: KuDOS Pharmaceuticals Limited
• Treatments: Olaparib; Poly(ADP-ribose) Polymerase Inhibitors

Criteria

Inclusion Criteria:

• Advanced breast cancer with positive BRCA1 or BRCA2 status

• Failed at least one prior chemotherapy

• In investigators opinion, no curative standard therapy exists

• Measurable disease

Exclusion Criteria:

• Brain metastases

• Less than 28 days since last treatment used to treat the disease

• Considered a poor medical risk due to a serious uncontrolled disorder